Anti-EGFR [225]
Invented at
- Datasheet
- References (0)
- Inventor Info
Info
| Catalogue Number | 153506 |
| Antigen/Gene or Protein Targets | Epidermal Growth Factor Receptor |
| Synonyms | EGFR, ErbB-1, HER1 |
| Reactivity | Human |
| Relevance |
Mutations that lead to EGFR overexpression (known as upregulation) or overactivity have been associated with a number of cancers, including squamous-cell carcinoma of the lung, anal cancers, glioblastoma and epithelial tumors of the head and neck. These somatic mutations involving EGFR lead to its constant activation, which produces uncontrolled cell division. In glioblastoma a more or less specific mutation of EGFR, called EGFRvIII is often observed. Mutations, amplifications or misregulations of EGFR or family members are implicated in about 30% of all epithelial cancers. Monoclonal 225 is a classic reagent in tumor therapy with more than 100 published references. The human/mouse chimeric antibody known as Cetuximab was derived from this monoclonal antibody. |
| Host | Mouse |
| Subclass | IgG1 |
| Research Area | Cancer |
References
There are 0 reference entries for this reagent.
References: 0 entry
There is no reference for this reagent yet, feel free to use the button below to suggest one.
Add a reference
References: 0 entry
There is no reference for this reagent yet, feel free to use the button below to suggest one.
Add a reference